A week after first raising the flag on their newborn biotech, a pair of entrepreneurs unhatched a deal today to take down a drug program that has been gathering dust on Amgen’s R&D shelves for the past 7 years and test it as a new treatment for celiac disease.

…read more

Source: Amgen hands off an IL-15 drug–strings attached–for upstart effort on celiac disease


0 No comments